For decades, multiple sclerosis (MS) has been defined primarily by its symptoms, rather than its underlying biology. Now, a new study aims to challenge that approach, presenting evidence that MS may actually follow two distinct biological pathways. It’s a shift that could reshape how clinicians think about diagnoses, disease progression and treatment strategy.